A multicentre, two-part, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, tolerability and pharmacokinetics of the iNOS inhibitor GW274150 administered up to 120mg daily for 12 weeks in the prophylactic treatment of migraine.
Phase of Trial: Phase II
Latest Information Update: 30 Sep 2015
At a glance
- Drugs GW 274150 (Primary)
- Indications Migraine
- Focus Therapeutic Use
- 15 Oct 2008 Actual start date changed from Jan 2007 to Oct 2005 as reported by ClinicalTrials.gov
- 09 Jun 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov
- 01 Jun 2007 Status change from recruiting to in progress.